CD70 and neoplasm: Recent studies have profiled the cytokine/chemokine profile of several tumors to better identify targets for CAR T. For instance, given that CD70+ gliomas produce high levels of interleukin IL-8, Jin et al. generated anti-CD70 CAR T cells that express high levels of IL-8R, demonstrating a more efficient recruitment to the tumor site than CD70-CAR alone [2].